GlobeNewswire by notified

Global Health and Gavi Veteran Anuradha Gupta to Lead Global Immunization at Sabin

Share

WASHINGTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Veteran public health leader Anuradha Gupta, who has spearheaded a host of successful global initiatives to improve the health of women and children and boost vaccine access and uptake, has joined Sabin Vaccine Institute as President of Global Immunization. Gupta’s record of crafting and implementing creative solutions to seemingly intractable health challenges is particularly significant now with life-saving childhood immunizations sustaining their largest backslide in decades, fueled largely by the pandemic.

Gupta comes to Sabin after eight years with Gavi, the Vaccine Alliance, where she served as Deputy CEO and led efforts to center policies, programs and partnerships around vaccine equity, gender and communities. She also pioneered the concept of zero-dose children – those who have not received a single dose of the most basic vaccines – and drove efforts to create a new model of country-level partnerships.

“Anuradha Gupta is a stellar addition to Sabin’s executive management team at a time when vaccine access and equity, as well as misinformation, remain enormous challenges worldwide,” said Sabin CEO Amy Finan. “Anuradha’s visionary approach, expertise, and deep commitment to those we serve will help move the needle for global vaccination rates.”

Gupta said she’s excited for her role and will use her extensive experience to advance innovative approaches to improve vaccine access and uptake. “This is a watershed moment for immunization, and we must ensure that vaccines remain front and center on the global public health agenda,” said Gupta. “There’s still so much to be done to introduce, scale up and universalize the full range of vaccines, and Sabin will be a powerful catalyst for this critically important work.”

A recent United Nations report noted that in 2021, 25 million babies missed out on one or more doses of routine vaccinations for diseases such as measles, diphtheria, and whooping cough. Nearly 18 million of those children, many in low-income countries, were zero-dose, making them more vulnerable to deadly and debilitating infectious diseases, and also, spurring fears of diseases such as polio and measles reemerging in non-endemic countries. 

“Fighting and finishing polio in India with an oral vaccine developed by Dr. Sabin is an unforgettable part of my public health journey,” Gupta recalls. “So, I am delighted to join an institution that is dedicated to advancing Dr. Sabin’s legacy by harnessing the full power of vaccines to save lives.”

Under Gupta’s leadership, Gavi won many accolades and rolled out a new framework for partner engagement that has helped bolster country ownership of Gavi-supported programs and improved accountability for results. Those achievements contributed to Gavi receiving the prestigious Lasker-Bloomberg Public Service Award in 2019 for providing sustained access to childhood vaccines in the world’s poorest countries. 

“Her willingness to expand the tent to include global players from various sectors is laudable and has measurably improved outcomes in many of these countries,” said Dr. Regina Rabinovich, MD, MPH, chair of the Sabin Board of Trustees. “Anuradha’s work exemplifies Sabin’s commitment to champion evidence-based solutions for immunization in low and middle-income countries and to build partnerships delivering lasting impact in these places.”

Gupta’s most recent initiative to focus on children who have not received a single shot is audacious for its ambition and scope. She was the guiding force behind Gavi’s $500 million Equity Accelerator Fund which includes an innovative program aimed at reaching zero-dose children in conflict zones and drought-afflicted areas in the Sahel region and the Horn of Africa.

Gupta pointed out that children who had been deprived of a single shot accounted for half of vaccine-preventable deaths and that targeting this population could be a game changer for reducing disease outbreaks and improving overall health security.

“These children live in communities that often face multiple deprivations so we must find a way to connect them to their first shot otherwise they miss their shot at a healthy future,” she said. “The Zero Dose Immunization concept goes beyond routine vaccines to connect families to other critical health care and humanitarian services, in consultation with communities, governments and other key groups.”

Prior to Gavi, Gupta served as Mission Director of the National Health Mission of India where she played a leading role in India’s efforts to eradicate polio, reduce maternal and child mortality, bring down fertility rates and revitalize primary health care. She served as a member of the Steering Committee for Child Survival Call to Action, co-chaired the Stakeholder Group for the 2012 London Summit on Family Planning and was a member of the Family Planning 2020 Reference Group. 

Gupta holds an MBA from the University of Wollongong in Australia and received executive education from the John F. Kennedy School of Government at Harvard University, Stanford Graduate School of Business and Maxwell School of Citizenship and Public Affairs at Syracuse University. In 2015, she was named one of “300 Women Leaders in Global Health” by the Global Health Centre of the Graduate Institute of International and Development Studies. She was profiled among the ten most influential women IAS officers in a recently released book – the Indian Administrative Services or IAS as it’s commonly called is India’s preeminent civil service.

In 2021, Gupta received the University of Wollongong’s Alumni Award for Social Impact. She was also conferred the highest civilian award for public service by the President of the Democratic Republic of the Congo and the Cross of Labour by the President of Laos for contributions to the health of the people in that country. In September 2022, she was awarded the Advance Global Australian Award, in recognition of the global impact of her many accomplishments.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world.

For more information, visit http://www.sabin.org and follow us on Twitter @SabinVaccine.

Media contact:

Rajee Suri
rajee.suri@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a2bfd118-42e2-4ff5-b2c1-92fd13e316cf

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sampo plc’s share buybacks 02/12/20225.12.2022 07:30:00 CET | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 05/12/2022 at 08:30 am Sampo plc’s share buybacks 02/12/2022 On 02/12/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)13,82248.47AQEU30,08648.47CEUX15,16048.50TQEX71,56748.46XHELTOTAL130,63548.47 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 16,932,474 Sampo A shares representing 3.18 per cent of the total number of shares in Sampo plc. Details of

CGG Announces New Integrated Multi-Client Data Project in Southeast Arizona to Support Mining Industry5.12.2022 07:30:00 CET | Press release

Paris, France – December5, 2022 CGG, a global technology and Earth sciences leader, has announced a new multi-client data project in Southeast Arizona focusing on exploration and development in the mining industry. The project, supported by industry funding and available to license now, will begin immediately, with final products scheduled for delivery through CGG’s proprietary GeoVerse™ platform. Dechun Lin, EVP, Earth Data, CGG, said: “Our Southeast Arizona data project represents a significant step forward in our strategy to provide integrated data solutions for the mining industryand is an innovative and effective model to improve data access in critical mining regions.” As part of this project, CGG will acquire over 270,000 line-kilometers of new airborne multi-physics data, including aeromagnetic, radiometric and airborne gravity data. CGG’s extensive team of subsurface experts and data scientists will integrate this data set with 50,000 km2 of satellite imagery, multispectral da

Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer5.12.2022 07:15:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been treated with androgen-receptor pathway inhibitor (ARPI) therapy1 Pluvicto becomes the first PSMA-targeted radioligand therapy to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy1, addressing a significant unmet need2 Findings to be presented at an upcoming medical meeting and submitted to regulatory authorities for approval in 2023 Novartis is advancing a broad portfolio of radioligand therapies to treat cancer and is investing in manufacturing capacity to meet the growing global demand for treatment Basel, December 5, 2022 — Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. Pluvic

Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning5.12.2022 07:00:00 CET | Press release

QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ, Switzerland's first approved dual orexin receptor antagonist, offers a new targeted mechanism of action that decreases nighttime overactive wakefulness in insomniaIdorsia Switzerland – led by General Manager Alice Huisman – aims to make QUVIVIQ available to patients with chronic insomnia disorder in Switzerland around mid-2023 Allschwil, Switzerland – December 5, 2022 Idorsia Ltd (SIX: IDIA) today announced that Swissmedic has granted marketing authorization for QUVIVIQ™ (daridorexant) for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.1 Chronic insomnia disorder is one of the most prevalent sleep disorders in Europe, affecting between 6%-12% of the adult population,2 and impacting both physical an

ForFarmers N.V.: ForFarmers convenes Extraordinary General Meeting of Shareholders on 17 January, 20235.12.2022 07:00:00 CET | Press release

Lochem, 5 December, 2022 ForFarmers convenesExtraordinary General Meeting of Shareholders on17 January, 2023 ForFarmers N.V. announces that Extraordinary General Meeting of Shareholders will be held (as a virtual meeting) on Tuesday 17 January, 2023, starting at 10.00 am (CET) in relation to the appointment of Theo Spierings as member of the Executive Board (CEO). The convocation announcement and the agenda and explanatory notes to the agenda are available via the corporate website of ForFarmers (www.forfarmersgroup.eu/en) under Investors / General Meeting of Shareholders. This press release contains information that qualifies as inside information within the meaning of Article 7 paragraph 1 of the EU Market Abuse Regulation. Note to the editor / For additional information: Caroline Vogelzang, Director Investor Relations M: 0031 6 10 94 91 61 E: caroline.vogelzang@forfarmers.eu Company profile ForFarmers N.V. (‘ForFarmers’, Lochem, the Netherlands) is an internationally operating feed